New-Onset Inflammatory Bowel Diseases Among IL-17 inhibitors-Treated Patients: Results From The Case-Control MISSIL Study.
Fiche publication
Date publication
novembre 2021
Journal
Rheumatology (Oxford, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, Baudart P, Bauer É, Claudepierre P, Constantin A, Dernis E, Felten R, Gaudin P, Girard C, Gombert B, Goupille P, Guennoc X, Henry-Desailly I, Jullien D, Karimova E, Lanot S, Le Dantec L, Pascart T, Plastaras L, Sultan N, Truchet X, Varin S, Wendling D, Gaboriau L, Staumont-Sallé D, Peyrin-Biroulet L, Flipo RM
Lien Pubmed
Résumé
To describe new-onset inflammatory bowel diseases (new IBD) in patients treated with interleukin 17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life.
Mots clés
IL 17 inhibitor, inflammatory bowel disease, psoriasis, psoriatic arthritis, real-world, secukinumab, spondyloarthritis
Référence
Rheumatology (Oxford). 2021 Nov 3;: